文献速递头颈外科

患者对ctHPVDNA引导下HPV阳性口咽癌监测的体验

Patient Experiences With ctHPVDNA-Guided Surveillance for HPV-Positive Oropharyngeal Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-10-29

该混合方法横断面访谈研究在单一三级学术癌症中心纳入20例接受过ctHPVDNA监测的HPV阳性口咽癌成人患者,通过半结构化访谈和迭代竞价评估自付支付意愿。研究归纳出五大主题:对检测的广泛支持、癌症旅程本身的情感困扰、对肿瘤团队信任超越检测本身、检测作为标准治疗的补充而非替代、对经济毒性的敏感。中位每检测支付意愿为325美元(范围0-9000美元)。

要点

  • 患者普遍支持ctHPVDNA监测,但对其准确性认知与个人体验存在不一致。
  • 对临床医生的信任可缓解由检测结果困惑或不准确带来的困扰。
  • 患者视ctHPVDNA检测为标准监测的补充而非替代,并关注经济可及性。

核心结论

  • 患者对ctHPVDNA引导的监测表达强烈支持,对临床医生的信任似乎可缓解与困惑或不准确检测结果相关的困扰。
  • 使用ctHPVDNA检测的临床医生应熟悉并清晰沟通其优势与局限性,以优化临床获益。

研究设计与样本

  • 混合方法横断面访谈研究,于2025年6月至8月在单一三级学术癌症中心开展。
  • 纳入20例接受过至少1次监测性ctHPVDNA检测(入组前3个月或更早)的HPV阳性口咽癌成人患者,采用目的性抽样确保体验多样性。
  • 通过半结构化访谈收集资料,采用分类归纳法从编码转录中提炼主题与子主题;采用迭代竞价法评估自付支付意愿。

主要发现

  • 20例参与者中位年龄58岁(IQR 55-70岁),16例男性(80%)。
  • 8例(40%)为真阴性ctHPVDNA结果,6例(30%)为真阳性,4例(20%)为假阴性,2例(10%)为假阳性。
  • 归纳出五大主题:对检测的广泛热情与支持;困扰作为癌症旅程本身情感波动的固有部分;对肿瘤团队的信任超越对检测本身的信任;检测作为标准治疗的有价值补充;对经济毒性的敏感。
  • 中位每检测自付支付意愿为325美元(范围0-9000美元)。

临床怎么用

  • 临床医生使用ctHPVDNA监测时应熟悉并清晰沟通检测的优势与局限性,以优化临床获益。
  • 应重视患者对检测准确性的认知差异,并通过清晰沟通增强患者对临床团队解读结果的信任。
  • 应将ctHPVDNA检测定位为标准监测的补充而非替代,并关注检测的经济可及性与公平性。

局限性

  • 研究在单一三级学术癌症中心开展,样本量20例,结果外推需谨慎。
  • 采用目的性抽样,可能影响结果的代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Circulating tumor human papillomavirus DNA (ctHPVDNA) is a potential biomarker for surveillance of HPV-positive oropharyngeal cancer. Despite its growing clinical use, patient experiences are not well characterized, and understanding patient perspectives of ctHPVDNA-guided surveillance is essential to guiding its appropriate use while mitigating potential harms. OBJECTIVE: To characterize patient experiences with ctHPVDNA-guided surveillance. DESIGN, SETTING, AND PARTICIPANTS: A mixed-methods cross-sectional interview study in adults treated for HPV-positive oropharyngeal cancer with 1 or more surveillance ctHPVDNA test 3 or more months before enrollment conducted in June through August 2025 in a single tertiary academic cancer center. Purposive sampling ensured representation of diverse patient experiences. EXPOSURES: One semistructured interview regarding experiences with ctHPVDNA-guided surveillance. Willingness to pay (WTP) out of pocket was assessed using iterative bidding. MAIN OUTCOMES AND MEASURES: Themes and subthemes were derived from coded interview transcripts using a categorical inductive approach. RESULTS: Among 20 participants (median age, 58 years [IQR, 55-70 years]; 16 males [80%]), 8 (40%) had true-negative ctHPVDNA test results, 6 had true-positive results (30%), 4 had false-negative results (20%), and 2 had false-positive results (10%). Five major themes emerged: (1) broad enthusiasm and support for ctHPVDNA testing, with a common assumption that more and earlier disease-related information is beneficial, and appreciation for the reassurance of negative test results (discordance between support for testing in general and personal experiences of test accuracy was observed); (2) distress as inherent to the emotional variability of the cancer journey itself, such that anxiety associated with ctHPVDNA testing was considered attributable to cancer survivorship rather than to the test; (3) trust in the oncology team supersedes trust in test itself, whereby clinicians were trusted to appropriately interpret potentially confusing results (this trust was enhanced by clear communication); (4) test as a valuable add-on to standard care, which should enrich, but not replace, standard surveillance; and (5) sensitivity to financial toxicity, with strong support for accessible and equitable testing. The median per-test WTP was $325 (range, $0-$9000). CONCLUSIONS AND RELEVANCE: This study found that participants expressed strong support for ctHPVDNA-guided surveillance. Trust in clinicians appeared to mitigate distress related to confusing or inaccurate test results. Clinicians using ctHPVDNA testing should be familiar with and clearly communicate its strengths and limitations to optimize clinical benefit.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Fleming GE, Roth H, Hanna GJ, et al. Patient Experiences With ctHPVDNA-Guided Surveillance for HPV-Positive Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42955024. doi:10.1001/jamaoto.2026.3379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。